Cefotaxime

Common Uses

Cefotaxime is a cephalosporin antibiotic prescribed to treat serious infections caused by bacteria. It works by killing bacteria or preventing their growth. It is commonly used for the following conditions:

• Respiratory infections: Such as pneumonia and other infections of the lower respiratory tract.
• Urinary tract infections: Including infections of the bladder or kidneys.
• Skin infections: Treatment of bacterial infections affecting the skin and underlying tissues.
• Bone and joint infections: Addressing bacterial growth in the skeletal system.
• Internal infections: Including intra-abdominal infections like peritonitis.
• Central nervous system infections: Such as meningitis.
• Bloodstream infections: Also known as septicemia.
• Sexually transmitted infections: Specifically gonorrhea.

Surgical Prevention

In some cases, healthcare providers use cefotaxime before or during certain surgical procedures. This is done to help prevent the patient from developing a bacterial infection following the operation.

Important Considerations

Cefotaxime is only effective against bacterial infections. It will not work for viral infections, such as the common cold, flu, or other respiratory viruses. Using antibiotics when they are not needed increases the risk of developing an infection later that resists antibiotic treatment.

Mechanism of Action

Cefotaxime belongs to a class of medications known as cephalosporin antibiotics. It is considered bactericidal, meaning it works by directly killing bacteria rather than just stopping their growth.

Disrupting the Bacterial Cell Wall

Bacteria require a sturdy outer layer called a cell wall to survive and protect themselves from their surroundings. Cefotaxime works by binding to specific proteins within the bacterial cell that are responsible for constructing this wall. By blocking these proteins, the medication prevents the bacteria from properly forming the structural components needed for a stable wall.

Bacterial Death

When the cell wall is weakened or incomplete, the bacteria cannot withstand the internal pressure of their own cells. This causes the bacteria to burst and die, which helps the body's immune system clear the infection.

Targeted Use

Cefotaxime is effective against a broad range of bacteria. However, it is important to note that this medication only treats bacterial infections. It does not work against infections caused by viruses, such as the flu or the common cold.

Common Side Effects

The following side effects are common and should be reported to a healthcare provider if they persist or become bothersome:

• Pain, redness, or swelling at the injection site
• Nausea or vomiting
• Mild diarrhea
• Stomach pain
• Headache
• Vaginal itching or discharge

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Severe stomach cramps and watery or bloody diarrhea
• Skin rash, hives, or itching
• Swelling of the face, lips, tongue, or throat
• Difficulty breathing or swallowing
• Unusual bruising or bleeding
• Seizures
• Yellowing of the eyes or skin
• New or worsening signs of infection, such as fever or sore throat

Allergic Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics. Before therapy begins, it is important to identify any previous hypersensitivity reactions to cefotaxime, cephalosporins, penicillins, or other drugs. There is a known risk of cross-sensitivity among these classes of antibiotics.

Clostridioides difficile-Associated Diarrhea

Nearly all antibacterial agents, including cefotaxime, can cause Clostridioides difficile-associated diarrhea (CDAD). This condition ranges in severity from mild diarrhea to fatal colitis. It occurs because the antibiotic alters the normal flora of the colon, allowing C. difficile to overgrow. CDAD has been reported to occur more than two months after the completion of antibiotic treatment.

Neurological Risks

The use of high doses of cefotaxime, particularly in individuals with impaired kidney function, may lead to encephalopathy. Potential symptoms of this neurological condition include:

• Impairment of consciousness
• Abnormal movements
• Convulsions

Kidney Impairment

In patients with significantly reduced renal function, the dosage of cefotaxime must be adjusted. Prolonged use or high doses in these patients may increase the risk of toxicity. Monitoring of kidney function is often recommended during the course of treatment.

Blood Count Monitoring

Granulocytopenia (a decrease in white blood cells) and agranulocytosis can develop, especially during long-term therapy. For treatment courses lasting longer than 10 days, regular monitoring of blood counts is typically performed.

Administration Precautions

Very rapid injection of cefotaxime (in less than one minute) through a central venous catheter has been associated with life-threatening heart rhythm disturbances, also known as arrhythmias.

Pregnancy

There are no adequate and well-controlled studies of cefotaxime in pregnant women. Animal reproduction studies have not shown evidence of harm to the fetus; however, animal studies do not always predict how a human will respond. For these reasons, cefotaxime should be used during pregnancy only if a healthcare provider determines it is clearly needed.

Breastfeeding

Cefotaxime is excreted in human milk in low concentrations. The use of this medication while breastfeeding should be approached with caution. Potential risks to the nursing infant include:

• Changes in the infant's natural gut bacteria, which may lead to diarrhea.
• The possibility of the infant developing an allergic sensitivity to the medication.

Individuals who are breastfeeding should discuss the risks and benefits with their healthcare provider before using cefotaxime.

Available Forms

Cefotaxime is administered by injection and is available in the following forms:

• Powder for Injection: This form is supplied in vials and must be mixed with a sterile liquid before use. It can be administered into a muscle or into a vein.
• Premixed Solution: This form is available as a sterile solution in plastic containers for intravenous infusion.

This medication is intended for use in a hospital or clinical setting under the supervision of a healthcare provider.

FDA Approval Status

Cefotaxime is an FDA-approved antibiotic belonging to the third-generation cephalosporin class. It is administered by injection, either intravenously or intramuscularly, to treat various systemic and localized bacterial infections.

Approved Indications

The FDA has approved cefotaxime for the treatment of the following conditions when caused by susceptible organisms:

• Lower respiratory tract infections
• Urinary tract infections
• Gynecologic infections
• Bacteremia and septicemia
• Skin and skin structure infections
• Intra-abdominal infections
• Bone and joint infections
• Central nervous system infections, including meningitis

Additionally, it is indicated for perioperative prophylaxis to reduce the risk of infection in patients undergoing certain surgical procedures.

Regulatory Safety Information

Cefotaxime does not carry any boxed warnings, which are the most serious warnings issued by the FDA. There are no Risk Evaluation and Mitigation Strategies (REMS) required for this medication. While the original brand-name version of this drug has been discontinued in the United States, generic formulations remain FDA-approved and available for clinical use.

Methods of Delivery

Cefotaxime is administered intravenously through two main methods depending on the required dose and the patient's clinical needs:

• Intravenous Bolus: The medication is injected directly into a vein or through an established IV line over a period of 3 to 5 minutes.
• Intravenous Infusion: The drug is diluted in a larger volume of fluid and delivered as a drip over a longer period, usually 20 to 30 minutes.

Preparation for Injection

The medication often comes as a sterile powder that must be dissolved in a compatible liquid before administration. Common diluents include sterile water for injection, 0.9% sodium chloride (normal saline), or 5% dextrose. Healthcare providers must inspect the resulting solution for any visible particles or discoloration before use; the solution should typically be clear or light amber.

Administration Schedule

The timing of IV doses is determined by the severity of the infection. It is commonly administered every 6 to 12 hours. For patients undergoing surgery, a single IV dose may be administered 30 to 90 minutes before the start of the procedure to help prevent postoperative infection.

Safety and Monitoring

Intravenous administration should be performed by trained healthcare professionals in a clinical setting. If the medication is administered at home, it is vital to follow all instructions for sterile preparation and the safe disposal of needles and supplies. Patients should monitor the injection site for signs of irritation, such as pain, swelling, or redness, and report these to a healthcare provider immediately.